Fig. 5

Patient plasma was analyzed by ProSeek proteomics at baseline (pre) and after 3 weeks post treatment initiation (post) and fold changes were calculated for these time points for each analyte. The fold change of analytes were then correlated to the fold change of gMDSCs (CD11b+CD14−CD33+HLA-DR−) pre and at 3 weeks post treatment initiation using Spearmans test for nonparametric samples. GraphPad Prism was used for statistical calculations